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Abstract
Background: Ablation of the low-affinity receptor subunit for leukemia inhibitory factor (LIFR)
causes multi-systemic defects in the late gestation fetus. Because corticosterone is known to have
a broad range of effects and LIF function has been associated with the hypothalamo-pituitary-
adrenal axis, this study was designed to determine the role for LIFR in the fetus when exposed to
the elevated maternal glucocorticoid levels of late gestation. Uncovering a requirement for LIFR in
appropriate glucocorticoid response will further understanding of control of glucocorticoid
function.
Methods: Maternal adrenalectomy or RU486 administration were used to determine the impact
of the maternal glucocorticoid surge on fetal development in the absence of LIFR. The mice were
analyzed by a variety of histological techniques including immunolabeling and staining techniques
(hematoxylin and eosin, Alizarin red S and alcian blue). Plasma corticosterone was assayed using
radioimmunoassay.
Results:  Maternal adrenalectomy does not improve the prognosis for LIFR null pups and
exacerbates the effects of LIFR loss. RU486 noticeably improves many of the tissues affected by
LIFR loss: bone density, skeletal muscle integrity and glial cell formation. LIFR null pups exposed
during late gestation to RU486 in utero survive natural delivery, unlike LIFR null pups from
untreated litters. But RU486 treated LIFR null pups succumb within the first day after birth,
presumably due to neural deficit resulting in an inability to suckle.
Conclusion: LIFR plays an integral role in modulating the fetal response to elevated maternal
glucocorticoids during late gestation. This role is likely to be mediated through the glucocorticoid
receptor and has implications for adult homeostasis as a direct tie between immune, neural and
hormone function.
Background
Glucocorticoids (GC's) are the effectors of stress and nec-
essarily impact multiple target tissues during normal func-
tion. Regulation of GC levels occurs through the
hypothalamo-pituitary-adrenal axis (HPA). Recent evi-
dence indicates that the cytokine, leukemia inhibitory fac-
tor (LIF) and its functional binding to the high affinity
receptor, a heterodimer between low-affinity LIFR and
glycoprotein 130 (LIFR:gp130), are players within the
HPA cascade of events. The ligands ciliary neurotrophic
factor (CNTF), cardiotrophin-1 (CT-1) and a novel neuro-
trophin set, known alternatively as NNT-1/BSF3 and CLF/
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CLC, also function through the high affinity LIFR:gp130
heterodimeric receptor but require a third ligand-binding
but non-signaling subunit [1–4]. Oncostatin M (OSM)
utilizes LIFR:gp130 as an alternative receptor complex for
OSM signaling in humans [5], but not in mice [6]. Thus,
in mice LIFR:gp130 is obligatory for signaling induced by
LIF, CNTF, CT-1 and CLF/CLC. Signaling proceeds
through the Janus kinase/signal transducers and activators
of transcription (JAK/STAT) or the ras-mitogen-activated
protein (MAP) kinase pathways [for a review see [7]].
LIF and LIFR are functionally expressed in rodent tissues
that are central to GC production: the hypothalamus [8]
and pituitary [9–12]. LIF works in synergy with corticotro-
pin-releasing hormone (CRH) in the hypothalamus to
increase pituitary pro-opiomelanocortin (POMC) and,
ultimately, pituitary adrenocorticotrophin hormone
(ACTH) [9,11,13–16]. LIF also stimulates POMC gene
expression directly in the pituitary [9,11,15,17]. LIF up-
regulates pituitary prohormone convertase (PC1). Subse-
quently, PC1 goes on to facilitate POMC processing to
ACTH [18] within the pituitary. LIF promotes survival of
magnocellular vasopressinergic neurons in the hypothala-
mus [19] which ultimately also positively influences
ACTH level. Thus, it is well documented in rodents that
signaling through the LIFR:gp130 heterodimer in the
hypothalamus and pituitary leads to adrenal GC produc-
tion via elevated ACTH. Other LIF effects that may influ-
ence the stress response through actions in the rodent
nervous system are a LIF induced increase in acetylcholine
[20] and LIF induced decreases in neuropeptide Y and
tyrosine hydroxylase [21]. LIFR:gp130 signaling has
strong effects in systems peripheral to but influenced by
the HPA including reproductive, skeletal, nervous, neu-
romuscular, cardiovascular, hematopoietic, immune and
metabolic systems, with influences on both development
and adult homeostasis [for reviews see [7,22–27]].
Animal models of LIF over expression and ablation have
confirmed importance in stress regulation. Adult mouse
LIF over expression mediated by transfer of LIF over
expressing hematopoietic cells results in a lethal, multi-
systemic phenotype that includes small adrenals with a
loss of the innermost cortical layer [28]. Pituitary specific
LIF over expression leads to a Cushing's Syndrome-like
condition of GC hyperactivity [29,30]. LIF null adult mice
have normal or slightly reduced basal ACTH and GC con-
centrations, and are unable to respond to acute stress by
increased ACTH. Basal POMC is reduced, but inducible
upon stress [16]. Thus, an obligatory function of LIF may
be in the processing of POMC to ACTH during acute
stress.
Null mutation of LIFR results in neonatal death and
defects in many systems including absence of glial cells,
osteoporosis, glycogen hyper-synthesis, placental defects
[31] and loss of motor neuronal subsets that cripple suck-
ling ability [32]. In all of the systems affected as a biolog-
ical consequence of LIFR loss, an explanation of the
mechanism of action can be designed around direct
action of LIFR in each system. However, when considered
as a whole, direct, non-redundant obligatory LIFR func-
tion in such diverse systems makes little evolutionary
sense. LIFR function within the stress response system
could be a unifying element in many of the diverse biolog-
ical consequences of LIFR loss. Among the defects seen
upon developmental LIFR loss, all but the loss of suckling
ability and placental changes mirror reported effects of
GC excess in the adult. This study explores the effect of
alteration of the GC environment during late gestation,
with the expectation that suppression of GC effects will
improve the LIFR null newborn phenotype and identify
LIFR as an obligatory player in concert with the maternal
GC surge during late gestation development. To link LIFR
function with GC function we have manipulated the late
gestation maternal steroid profile by maternal adrenalec-
tomy or RU486 administration to determine if the mater-
nal GC surge impacts fetal well being in the absence of
LIFR and functional LIFR:gp130 signaling. RU486 admin-
istration during late gestation results in improved devel-
opment of bone, skeletal muscle, and glial cells in LIFR
null fetuses.
Methods
Mice
The mice used in this study were first described in 1995
[31]. Disruption of the first coding exon with a promter-
less  β-galactosidase/neomycin resistance fusion cassette
[33] created a null allele for Lifr. AB1 ES cells, on a129S7/
SvEvBrd-Hprtb-m2 background, were used for targeting Lifr.
The mice were sent to the Induced Mutant Resource of the
Jackson Laboratory in 1994, from where one hetero-
zygous (Lifr +/-) male was received in 1997 to re-establish
the colony at the University of Washington. Since the ini-
tial germ line chimera, the line has been bred back to
C57BL/6 for over 5 generations and there have been sev-
eral generations of sibling matings. Thus, although exact
records were not kept, the mice are on a predominantly
C57BL/6 background (>96%). All work was carried out
following the Institutional Animal Care and Use Commit-
tee guidelines within an Association for Assessment and
Accreditation of Laboratory Animal Care approved spe-
cific pathogen-free facility.
Lifr +/- females were mated to Lifr +/- males and the day
of plug (E0.5) recorded. Pups were either born naturally
or derived by Cesarean section (C-section) on E18.5 as
described [34]. The E18.5 pups were placed in a dish on
ice to induce hypothermia and sleep followed by euthana-
sia through decapitation. Tail snips were used forReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/43
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genotyping by polymerase chain reaction as previously
described [31].
Hormone manipulation
E16.5 was chosen as the starting point for each treatment
since no phenotypic differences among the Lifr genotypes
was detected at this point. Noticeable differences were
seen beginning on E17.5 [31]. Also, fetal feedback control
of GC production is established on E16.5 coincident with
the initiation of the maternal surge [35]. Adrenalectomy
of E16.5 pregnant mice was performed as previously
described [36]. Briefly, adult mice were anesthetized using
ketamine and xylazine. The site was prepped and a small
incision (~1 cm) made on the right side of the spine over
the upper kidney. The adrenal gland was located and
excised, with care taken to avoid damage of blood vessels.
Following removal of the right adrenal, one suture was
placed to close the muscle incision. The adrenalectomy
procedure was repeated on the left side. The skin was
closed using a 9 mm wound clip. No hormonal support
was provided. Pups were born following C-section on
E18.5. Two litters containing in total 3 Lifr +/+, 6 Lifr +/-
and 5 Lifr -/- pups were studied. Within litter Lifr +/+ and
+/- pups served as controls since there has been no detect-
able gene dose effect between Lifr +/+ and +/- at this stage
of development. No mock surgeries were performed.
Lyophilized RU486 (National Hormone and Peptide Pro-
gram) was dissolved to 20 mg/ml in ethanol and diluted
to 25 µg/ml in peanut oil. RU486 was administered as a
subcutaneous injection of 2.5 µg/mouse in 0.1 ml of pea-
nut oil on E16.5 and E17.5. Pups were born by natural
delivery on E18.5. Three litters containing in total 5 Lifr +/
+, 10 Lifr +/- and 4 Lifr -/- pups were studied. These were
compared with their littermates and to control groups that
experienced no hormone intervention. C-section delivery
of untreated control animals was performed on E18.5.
Three untreated control litters containing in total 6 Lifr +/
+, 3 Lifr +/- and 7 Lifr -/- pups were studied. Comparisons
were made between Lifr -/- versus Lifr +/+ and +/- litter-
mate controls.
Histology
E18.5 fetuses were fixed in 4% paraformaldehyde in PBS
for paraffin sectioning. Paraffin blocks were cut in 5–6 µm
sections, deparaffinized and hydrated to water prior to
staining. Sections were stained with hematoxylin and
eosin (H&E) or by periodic acid-Schiff (PAS). For PAS,
slides were placed in 0.5% periodic acid (Sigma) for 10
minutes. They were rinsed in water and placed in Schiff
reagent (Sigma) for 30 minutes, washed and counter-
stained with Gill 3 hematoxylin (Sigma). Slides treated
with diastase to digest sugars were compared with
untreated slides to control for specificity of PAS staining.
Immunohistochemistry was performed using antibodies
to ACTH (rabbit polyclonal anti-ACTH; Chemicon Inter-
national) or glial fibrillary acid protein (rabbit polyclonal
anti-GFAP; Chemicon International). Antibody binding
was visualized using the Universal Quick Kit with
NovaRed (Vector).
Skeletal preparations followed a combination of the pro-
tocols of Gendron-Maguire et al. [37] and Rijli et al. [38].
Briefly, the fetuses were eviscerated, the skin was removed
and they were fixed in 100% ethanol for four days fol-
lowed by three days in acetone. They were rinsed with
water and transferred to staining solution which con-
tained 1 volume of 0.1% Alizarin red S (Sigma), 1 volume
of 3% alcian blue (Sigma), 1 volume acetic acid and 17
volumes ethanol. After staining for 10 days, the skeletons
were rinsed with water, followed by immersion in 20%
glycerol in 1% potassium hydroxide overnight at 37°C
and held at room temperature until cleared. At this point
they were passed through 50, 80 and 100% glycerol for
storage.
Only within litter mice were compared. Following detec-
tion of differences, an array of slides and tissues were pre-
sented to a pathologist blinded to genotype for
confirmation. The numbers of pups observed for each
parameter are listed in Table 1.
Table 1: LIFR Genotypes of Tissues Assessed by Immunolabeling and Histochemistry
No of animals
Control Adrenalectomy RU486
Tissue +/+ +/- -/- +/+ +/- -/- +/+ +/- -/-
B o n e 6363655 1 0 4
Spinal cord 1 1 2 1 1 2
Skeletal 
muscle
216 112
Pituitary 1 1 2 1 1 2
Adrenal 4 1 7 4 3 1 1 2Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/43
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Radio-immune assay (RIA) for corticosterone
Samples were run at a dilution of 1:200 using a kit (ICN)
in the recommended diluent using the kit protocol. The
standards spanned 0.125–5.00 ng/ml. All samples were
run in the same assay with high and low controls. Sam-
ples, standards and controls were run in duplicate and
results averaged. Blanks were run in quadruplicate and
results averaged. The standard curve was calculated using
a four-parameter logistic curve fit. All samples were
between 25–87% bound. The coefficient of variance
between duplicate samples was 5% or less for all samples,
standards and controls.
Results
Consistent Phenotype
The phenotype due to LIFR loss has remained consistent
throughout the transition through three separate institu-
tions and between the transition from, 129S7/SvEvBrd-
Hprtb-m2 to greater than 96% C57BL/6. In particular, LIFR
null mutation remains a neonatal lethal with associated
osteopenia and an absence of glial cells in late gestation,
as described below.
Effect of Altered GC Action
Two approaches were used to attempt to reduce the effects
of the maternal GC surge on the fetus. The first approach
toward manipulating the maternal GC surge was maternal
adrenalectomy on E16.5, without further GC support.
Control Lifr -/- pups could not be identified by gross mor-
phology or behavior. Lifr -/- pups from adrenalectomized
mothers were noticeably smaller than the littermates and
did not move vigorously. The gross morphology and
behavior could accurately identify the 4 Lifr -/- pups fol-
lowing treatment that presumably heightened the fetal
exposure to GC's. Thus, the impact of maternal adrenalec-
tomy on the fetuses appeared to have a selective negative
effect on the development of the Lifr -/- pups.
The second approach was to administer RU486 on E16.5
and E17.5 to block the effects of the GC surge at the GR in
the mother and in the fetus, following placental transport
[39]. We wanted to find a dose of RU486 that allowed lit-
ters to be born on E18.5 by natural delivery since E18.5 is
the earliest day of natural birth seen in unmanipulated
pregnancy. A dose of 5–10 µg per mouse generally, but
not consistently, caused abortion on E17.5. Pups were
born after E18.5 following a dose of 1.0 µg RU486 per
mouse per day. A 2.5 µg per mouse dose induced birth on
E18.5. However, response throughout was individual.
A pregnant mouse was treated with RU486 on E16.5 and
17.5. Following natural delivery on E18.5, the one Lifr -/-
pup was indistinguishable from the littermates both by
size and vigor, but succumbed to the soporific effect of
hypothermia before its littermates. Subsequently, a fur-
ther four litters similarly treated with RU486 were born by
natural delivery and left with their mothers for four weeks.
Of the 37 pups that survived to weaning, none were Lifr -
/-. No pups were excluded from the litters on the day of
birth; however, the remains of dead pups were found the
following day. Only one pup found dead on the day after
birth was of sufficient quality to genotype, and, as
expected, it was Lifr -/-. Two more litters of RU486 treated
pups were born by natural delivery on E18.5. These litters
were taken on E18.5 for analysis. The mothers accepted all
the pups into the litters. Four pups had not suckled, as evi-
denced by the lack of milk in their stomachs, while the
other 8 had. All were otherwise clinically normal. Of the
four with no milk, three succumbed to hypothermia more
rapidly than the rest. These three proved to be Lifr -/-. The
one additional pup with no milk in its stomach, but that
resisted the effect of hypothermia the longest of the four
was Lifr +/-. All the littermates that had suckled and had
detectable milk in their stomachs were Lifr +/+ (2 pups) or
Lifr +/- (6 pups). Consequently, RU486 allowed the Lifr -
/- pups to survive natural delivery and maternal culling,
although they apparently succumbed due to an inability
to suckle.
Bone
There was no loss of density at the growth plate following
any of the treatments in the Lifr +/+ and +/- animals (Fig-
ure 1A,1C,1E). The expected loss of density was seen at the
growth plate in the untreated control and maternal
adrenalectomy exposed Lifr -/- pups (Figure 1B,1D). Fra-
gility may be increased in the adrenalectomy group as evi-
denced by broken mineralized bone at the growth plate,
presumably due to osteopenia combined with handling
post mortem. Of the 5 Lifr  -/- pups from pregnancies
where the mother was adrenalectomized, 4 had broken
bones once the staining was complete, whereas, no
stained bones from the Lifr +/+ and +/- littermates were
broken. In addition, all bones from both control and
RU486 exposed litters remained intact throughout the
staining process. RU486 treatment of the mother noticea-
bly protected Lifr -/- pups from bone loss (Figure 1F),
although modest thinning could still be seen, suggesting
that protection was incomplete.
Glial Cell Formation
Consistent with previous findings, no GFAP positive cells
could be detected in the spinal cord of either of the Lifr -/
- untreated control animals. Ordinarily very few GFAP
positive cells are seen at this stage of development in wild
type animals, making detection of GFAP positive cells
dependent on particular spinal cord section viewed. Seven
control Lifr +/+, 5 control Lifr -/-, 8 RU486 exposed Lifr +/
+ and +/- and 11 RU486 exposed Lifr -/- spinal cord sec-
tions were immunolabeled. GFAP became detectable in
the sections from the two E18.5 Lifr -/- animals analyzedReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/43
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when the mother was given RU486 on E16.5 and 17.5 of
gestation (Figure 2). Although, immunolabeling was
reduced relative to that seen in wild type. GFAP immuno-
positive cells were often associated with blood vessels in
the spinal cord. Although staining was relatively spare in
all sections, complete absence of any labeling near vessels
was apparent in the control Lifr -/- spinal cord (Figure 2B).
Skeletal Muscle
Skeletal muscle integrity appeared compromised in the
control Lifr -/- animals relative to wild type (Figure 3A and
3B). This was evidenced by a frayed, granular appearance
with loss of staining intensity of muscle fibers in Lifr -/-
untreated controls. On closer examination, the individual
muscle fibers contained fine vacuoles formed within the
sarcoplasm (Figure 4B, arrows). Lifr -/- pups treated with
RU486 completely lacked this phenotype and appeared
normal. The characteristic appearance of skeletal muscle
in Lifr -/- mice may be due to altered metabolism as evi-
denced by glycogen accumulation. Modest, but inappro-
priate glycogen accumulation was also seen in Lifr  -/-
periodic acid-Schiff stained skeletal muscle (Figure 3B).
Glycogen was barely detectable in comparable tissues
from Lifr +/+ or +/- littermates (Figure 3A).
Pituitary ACTH
Immuno-staining for ACTH in the pituitary showed no
profound difference due to LIFR loss (Figure 4A and 4B).
Figure 1
Fetal protection from osteopenia through RU486 administration during late gestation. Mineralized bone is visual-
ized with Alizarin red S and cartilage with alcian blue. A. Tibia and fibula of an E18.5 Lifr +/+ untreated control mouse. Bone 
mineralization occurs throughout the length of the bone, including the epiphysis. The same can be seen for Lifr +/+ and Lifr +/- 
mice whether the mother was adrenalectomized on E16.5 of gestation (C) or received RU486 on E16.5 and E17.5 (E). B. An 
E18.5 Lifr -/- untreated control mouse littermate of the pup shown in A demonstrates mineralized bone loss at the growth 
plate. D. An E18.5 Lifr -/- littermate of the pup shown in C where the mother was adrenalectomized on E16.5 displays similar 
bone loss at the epiphysis as seen in B, but bones of the Lifr -/- mice in this group tend to be more fragile and show breaks 
within areas of osteopenia (arrow). F. A Lifr -/- E18.5 pup that was exposed to RU486 on E16.5 and E17.5. The epiphysis is 
modestly thinner than that of the wild type littermate (E), but mineralization at the growth plate is improved relative to the 
untreated control (B) or adrenalectomy treated (D) Lifr -/- pups. The size bar indicates 1 cm.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/43
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Treatment with RU486 resulted in apparent pituitary
ACTH up-regulation as evidenced by increased immu-
nolabeling regardless of genotype (Figure 4C and 4D).
The strongest ACTH immunolabeling was seen in the pars
intermedia of the anterior pituitary with scattered labeling
in the pars distalis. This was an appropriate pattern for the
corticotroph population. Thus, the corticotrophs did not
seem altered by LIFR loss using this method of assess-
ment. GC's induce negative feedback regulation on pitui-
tary ACTH production, as a mechanism for protecting
against GC overproduction. Because RU486 is a GR antag-
onist, it is known that administration can cause increased
pituitary ACTH production [41]. RU486 exposure
increased pituitary ACTH levels in both the Lifr +/+ and -
/- animals, as judged by the apparent increase in labeling
density through immunohistochemistry. Increased pitui-
tary ACTH indicates that, in the absence of LIFR, pituitary
ACTH could still be induced. However, this will require
measurement of POMC by quantitative methods.
Lung
Lung development in all the pups looked normal as
viewed on H&E stained thin sections. The lungs had
inflated and were indistinguishable between treatments
and genotypes (Figure 5).
Serum Corticosterone
Corticosterone levels in blood collected from untreated
control pups or pups from pregnancies where the mother
was adrenalectomized on E16.5 had no evident
Figure 2
GFAP expression in the spinal cord. A polyclonal antibody was used to label GFAP antigen expressing cells red. A. The 
spinal cord of an E18.5 Lifr +/+ untreated control mouse immunolabeled GFAP expressing cells surrounding a blood vessel in 
cross-section (arrow). B. Immunolabeling of a Lifr -/- control littermate of the pup in A. There are no detectable positive cells. 
The arrow indicates a blood vessel. C. A Lifr +/+ pup exposed to RU486. The arrows indicate positive cells associated with 
blood vessels. D. A Lifr -/- pup exposed to RU486 (littermate to the pup in C. The arrow indicates positive staining surrounding 
a blood vessel. The size bar indicates 50 µm.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/43
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correlation to Lifr  genotype, as evidenced by the trial
results from serum collected from only a few pups (Table
2.). Pups in the control and adrenalectomy groups were
born by C-section on E18.5 and the blood collected
within one hour of birth. The two pups in the RU486
group were born by natural delivery and were ex utero for
greater than one hour prior to euthanasia and blood
collection.
Discussion
The results implicate excess fetal GC response in late ges-
tation as the reason for the multi-systemic phenotypes in
the absence of LIFR. Maternal adrenalectomy worsens the
osteopenia, while maternal hormone suppression
through RU486 improves the presumed GC related
phenotypes: osteopenia, skeletal muscle integrity and
glial development. This was an improvement over the
poor prognosis for Lifr -/- newborns described initially
[31]. In that study, Lifr-/- pups rarely survived natural
delivery, but when they did, they were excluded from the
litter and died at variable times beginning one hour fol-
lowing birth. No pups survived through the night follow-
ing birth. The survival of Lifr -/- pups following RU486
treatment was similar to the phenotype seen in CNTFR
null mice where neuronal development was disrupted
which disallowed suckling [40]. This indicates that at least
some of the problems encountered with neuronal devel-
opment that affect normal suckling were not ameliorated
Figure 3
Skeletal muscle integrity. The primary views in all panels are stained by hematoxylin and eosin. A. Skeletal muscle is shown 
from an E18.5 untreated control Lifr +/- pup. The insert in the lower right is a PAS stain of a similar view in a Lifr +/+ E18.5 
untreated control. Note the absence of fuchsia staining glycogen stores. B. Lifr -/- skeletal muscle from an untreated control lit-
termate displays a separation of the muscle fibers that reveal small vacuoles present within the sarcoplasm (arrows). The insert 
in the lower right is a PAS stain of a similar view of a Lifr -/- E18.5 untreated control pup. Note fuchsia staining glycogen stores. 
C. Skeletal muscle from an E18.5 Lifr +/+ pup from a litter where the mother received RU486 on E16.5 and E17.5. D. Skeletal 
muscle from a RU486 treated Lifr -/- littermate to the pup viewed in panel C. The size bar indicates 100 µm.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/43
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by RU486. Neither adrenalectomy nor RU486 treatment
impact the apparent well-being of the Lifr +/+ or +/- litter-
mates. Excess GC activity due to LIFR loss is an unexpected
result since LIF gain-of-function mice develop a Cush-
ing's-like syndrome [29,30]. Thus, if the relationship were
simple, loss of LIFR function would predict development
of GC insufficiency. The observed GC activity excess sug-
gests that LIF and LIFR are integral to GC regulation, but
that the relationship is complex and that alterations in GC
response are likely to result from altered balance of the GC
response cascade induced both by gain and loss of LIFR
function.
There is a maternal GC surge beginning on E16.5, where
E0.5 is the day of vaginal plug following mating. A pri-
mary function of this surge is to allow development to
switch from growth to maturation of a number of systems
that will allow the pup to survive on separation from the
mother. Lung surfactant synthesis and connective tissue
maturation allow the lungs to become distensible and
capable of coping with high surface tension. In addition,
the maternal GC surge effectively leads to fetal glycogen
accumulation in the liver for energy demands at birth,
increased fetal bioavailable tri-iodothyronine from thy-
roxine to allow for an increased metabolic rate and ther-
mogenesis required at birth, maturation of the fetal small
gut to prepare for digestion, heightened fetal adrenal
Figure 4
ACTH expression in the pituitary. Immunolabeled ACTH positive cells are red. A. Anterior pituitary section from a Lifr +/
- untreated control mouse. The pars intermedia (pi) appears as a band to the left that contains many immunolabeled cells. The 
pars distalis (pd) contains scattered ACTH immuno-positive cells. B. Anterior pituitary from a Lifr -/- littermate to the pup in 
panel A. C. Anterior pituitary section from a Lifr +/+ pup where the mother received RU486 on E16.5 and E17.5. ACTH immu-
nolabeling is increased relative to panel A. D. An anterior pituitary section from a RU486 treated Lifr -/- littermate of the pup 
in panel C. All sections were processed by immunohistochemistry at the same time. The size bar indicates 200 µm.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/43
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medullar catecholamine release for control of the above
processes, maturation of fetal kidney function and a
switch to bone marrow hematopoiesis from the fetal liver
[reviewed by [41]]. The timing of this maternal surge sug-
gests that LIFR function is required at this point in devel-
opment as a moderator of the consequences of excess GC
level.
Mock adrenal surgeries were not performed on the mice.
Therefore, we do not know if stress of surgery alone is
enough to impact well-being in LIFR null mice. Progester-
one was administered in peanut oil following the same
regimen as RU486, but resulted in bone loss reminiscent
of the results following adrenalectomy (unpublished
observation). Thus, peanut oil alone is not responsible for
the improvements seen in the RU486 group and the effect
of excess progesterone provides further evidence that the
Figure 5
Lungs of E18.5 pups. All panels are stained by hematoxylin and eosin and indicate normal lung inflation in newborn pups. A. 
C-section derived wild type control pup. B. C-section derived Lifr -/- control pup. C. Lung of a wild type pup naturally delivered 
following exposure to RU486 in utero. D. Lung of a Lifr -/- pup naturally delivered following exposure to RU486 in utero. The 
size bar indicates 100 µm.
Table 2: Plasma Corticosterone Levels in E18.5 Pups (ng/ml)
Genotype Control Adrenalectomy RU486
(number of animals assayed)
Lifr +/+ 145 (1) 67 (2) 20 (1)
Lifr +/- 77 (1) 69 (2) -
Lifr -/- 74 (2) 92 (4) 75 (1)Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/43
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LIFR phenotype can worsen through endocrine
manipulation.
We previously reported that placental integrity is dis-
rupted at the LIFR null maternal-fetal interface [31]. In
that study, the maternal response to disorganized fetal
placental tissue was sufficient to protect the fetus from
malnutrition, since there was no detectable disruption of
fetal erythropoiesis. However, what this meant for relative
transport of RU486 or maternal mediators of fetal hor-
mone balance upon adrenalectomy is unknown. Maternal
adrenalectomy on E16.5 was a naïve approach toward
blocking the maternal GC surge. It likely had the effect of
increasing maternal ACTH levels [42] that would, in turn,
act on the fetal adrenal to synthesize corticosterone. This
may have been the source of the modestly elevated corti-
costerone level seen among the Lifr  null pups in the
adrenalectomy group. Although anecdotal, it would
appear the RU486 exposed wildtype animal cleared resid-
ual late gestation corticosterone following birth more
effectively than did the Lifr -/- littermate. Previous studies
measuring circulating insulin and glucose levels in C-sec-
tion derived E18.5 pups bore no apparent correlation to
Lifr genotype (unpublished observation). At the time it
appeared that plasma measurements in pups immediately
following C-section were an unreliable reflection of indi-
vidual condition and were likely to be a reflection of
maternal levels. An accurate picture of corticosterone lev-
els will probably require separation from the mother for
several hours.
RU486 was first explored as a GR antagonist and subse-
quently found to be both a GR and progesterone receptor
(PR) antagonist, with mild antagonistic effects on the
androgen receptor. In certain cases it can function as a
mild agonist. RU486 can bind to the hormone-binding
domain of both GR and PR. Although still able to localize
to the nucleus, it prevents subsequent transcription of GC
and progesterone responsive genes. It does not directly
antagonize the mineralocorticoid receptor (MR)
[reviewed by [43]].
Because RU486, along with antagonizing the GR antago-
nizes the PR, some of the RU486 benefit may be due to
antagonism of progesterone effects. Progesterone is inte-
gral to the hormonal milieu. It is processed to GC's
through the actions of 21 hydroxylase and 11 β-hydroxy-
lase [44] and it is an anti-GC [45–49] and an anti-miner-
alocorticoid (MC) [50–53]. Therefore, PR antagonism by
RU486 could increase GC and MC effects, although this is
the opposite of the phenotype seen. Progesterone inter-
acts synergistically with estrogen in bone remodeling [54],
while GC excess is implicated in osteoporosis. LIFR is
known to be important in the balance between bone
resorption and bone formation acting directly on osteob-
lasts [55–57]. Bone loss in the untreated control Lifr -/-
pups suggests a heightened response to GC rather than a
heightened response to the bone-remodeling effects of
progesterone. Whereas, protection by RU486 implies
antagonism of GR mediated bone loss, rather than antag-
onism of PR mediated bone remodeling. In addition, a
progesterone receptor knockout mouse model affects only
female mice with reported effects limited to organs of
reproduction causing anovulation, uterine hyperplasia
and inflammation, limited mammary development and
impaired sexual behavior [58]. There was no noticeable
difference in phenotype in the Lifr -/- pups due to gender
following any of the treatments (data not shown). Since
apparent defects due to LIFR loss arise during the late
gestation GC surge, while maternal progesterone levels are
declining in anticipation of birth and because phenotypes
that have been attributed in the literature to GC excess are
lessened through RU486 and the apparent heightened GC
response in Lifr -/- mice affects both sexes equally, it is
likely that RU486 attenuation of associated phenotypes is
primarily mediated through GR antagonism. However,
the interconnectedness of hormone action may also
include RU486 mediated PR antagonism as a means of
impacting the extent of GR-related effects.
The primary clinical utility of RU486 is PR antagonism to
induce early pregnancy abortion. Since the data were col-
lected from pups that were born early by natural delivery
(E18.5 versus E19.5–21.5) following RU486 treatment of
pregnant females, it can be assumed that the RU486 used
was an active PR antagonist, and, by association, an active
GR antagonist. The effective dose used in this study was
somewhere between 0.1 and 0.2 µg/gram/day for two
days. The dose was not administered by weight since lit-
ters vary in size and will have a large impact on maternal
weight in late gestation. 0.3 µg/gram/day has been
reported to induce abortion in 5% of mice during early
gestation following 3 days of administration [59]. The
dosage used in this study was able to induce pre-term
birth by natural delivery at a time when the pups were
able to survive ex utero (E18.5), but was well below the
dose used to achieve clinical abortion.
The apparent GC hyper-responsiveness in LIFR null pups
is probably not directly due to excess circulating corticos-
terone in the absence of LIFR. Instead, expression of GR
and subsequent GR induced transcription may be more
relevant than circulating GC level. Another consideration
is that the benefit of RU486 administration may be either
central within the HPA or can be due to peripheral GR
antagonism. Cardiac dysfunction has not yet been
explored in the LIFR null model. However, many of the
defects caused by gp130 loss are shared by mice with a
null mutation of LIFR, reflecting the heterodimeric rela-
tionship of LIFR and gp130 for functional LIFR:gp130 sig-Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/43
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naling. A recent cardiac muscle specific gp130 knockout
model develops normally [60]. Whereas, non-tissue spe-
cific gp130 knockout results in hypotrophic cardiac mus-
cle apparent by E15.5 [61]. This suggests that the effect of
gp130 knockout on cardiac development is mediated out-
side of cardiac tissue and the primary developmental
defect is peripheral to the heart. Given the improvement
in skeletal muscle noted in this study following RU486, it
would be reasonable to explore a central HPA defect fol-
lowing gp130 loss as the mediator of hypotrophic cardiac
development.
Muscle regeneration begins through the muscle precursor
satellite cells. Activation is followed by proliferation and
fusion with other satellite cells to form new myotubes.
Muscle regeneration is a dynamic process necessary in the
maintenance of muscle integrity. LIF and CNTF stimulate
muscle regeneration in vivo [62,63], as do other growth
factors; such as insulin-like growth factor [64,65]. The
power of LIF to regenerate muscle is seen in dystrophin
null mdx mice, where exogenous LIF regenerates atro-
phied diaphragm muscle [66]. LIF induced signaling
appears to be essential in muscle development as seen by
muscle atrophy in the absence of LIFR on E18.5. In the
absence of LIFR, muscle atrophy may be caused by GC
induced alteration of metabolism, which leads to glyco-
gen accumulation, inhibition of protein synthesis and
stimulation of protein degradation [67,68]. Because low
levels of RU486 can fully protect Lifr -/- fetal muscle from
the late gestation GC surge, the balance between hormone
function and muscle integrity appears both delicate and
direct.
GR expression is specific but widespread within neuronal
and glial cell populations. LIF is also responsible for
increased GFAP expression [69], while signaling through
LIFR:gp130 is critical in fostering the differentiation of
neuronal precursors into astrocytes [70] mediated
through STAT3 [71–74]. Glial cells respond to GC, which,
in turn, can affect transcriptional control of GFAP level
either positively or negatively [74]. The present study
shows that GC's can play a critical role in hindering astro-
cyte development in the absence of LIFR as seen through
the partial abrogation of this defect following exposure to
RU486 in Lifr -/- mice. RU486 crosses the blood-brain-
barrier and is present at only 28% of levels seen in the
serum [75]. Perhaps glial development would be further
improved in the presence of higher levels of RU486 were
these levels not abortive. The RU486 effect is not likely to
be mediated through PR in the Lifr -/- astrocyte precursors,
since astrocytes have low levels of PR's that are only
detectable in females [76].
The vigor displayed at birth by RU486 treated Lifr -/- pups
is striking and suggests sweeping improvement in well-
being. Pups of all Lifr genotypes are able to breathe well at
birth and Lifr +/+ and +/- pups thrive with no apparent
lung handicap. This indicates that the improvement due
to RU486 is implemented through modest alteration in
GC regulation since complete loss of GR function leads to
incomplete lung development at birth and impaired sur-
vival through atelectasis [77]. The neural compartment
may have been under-protected by RU486 due to partial
exclusion by the blood-brain-barrier, while bone and skel-
etal muscle, tissues exposed to higher levels of RU486,
were clearly protected. Hypothalamus and anterior pitui-
tary are also protected by the blood-brain-barrier. Eleva-
tion of ACTH in response to RU486 was apparent.
Consequently, very low levels of RU486 appear to
mediate partial neural normalization. Loss of neuronal
subpopulations integral to suckling need to be explored in
the RU486 late gestation pups, but the data suggest that
the health of this population is not directly influenced by
altered GC response.
Conclusions
In conclusion, many of the multi-systemic defects during
late gestation brought about by LIFR loss were attenuated
using maternal RU486 administration. Osteopenia is
reduced, muscle integrity is normal and glial cells are
forming. The mother can no longer detect abnormalities
in the LIFR null pups severe enough to stimulate culling
behavior. However, motor neuron deficit appears
functionally unaffected and the newborn pups still suc-
cumb through inability to suckle. These results indicate
that signaling through LIFR utilizing the LIFR:gp130 het-
erodimer is essential for an appropriate GC response dur-
ing development.
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